Andra AP fonden Buys 28,800 Shares of Insulet Corporation $PODD

Andra AP fonden boosted its stake in shares of Insulet Corporation (NASDAQ:PODD) by 50.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 86,400 shares of the medical instruments supplier’s stock after acquiring an additional 28,800 shares during the period. Andra AP fonden owned 0.12% of Insulet worth $26,674,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. True Wealth Design LLC boosted its holdings in shares of Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 72 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 69 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Insulet by 48.9% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 43 shares in the last quarter. Quent Capital LLC bought a new position in Insulet during the third quarter valued at approximately $49,000. Finally, Osterweis Capital Management Inc. bought a new position in Insulet during the second quarter valued at approximately $51,000.

Insider Buying and Selling at Insulet

In other news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PODD. Stifel Nicolaus reduced their price objective on Insulet from $370.00 to $350.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. Oppenheimer cut their target price on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating for the company in a report on Thursday, February 19th. BTIG Research restated a “buy” rating and issued a $380.00 price target on shares of Insulet in a research report on Wednesday, February 18th. Citigroup lowered their price objective on shares of Insulet from $380.00 to $345.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Finally, Wolfe Research lifted their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Twenty investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $354.57.

Insulet Stock Up 1.4%

NASDAQ:PODD opened at $251.50 on Friday. The company has a market cap of $17.71 billion, a price-to-earnings ratio of 71.86, a price-to-earnings-growth ratio of 1.48 and a beta of 1.41. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. The stock has a fifty day simple moving average of $269.07 and a 200-day simple moving average of $303.58.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company had revenue of $783.80 million for the quarter, compared to the consensus estimate of $768.31 million. During the same quarter last year, the firm posted $1.15 EPS. The firm’s revenue was up 31.2% compared to the same quarter last year. Analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.